DSS announces sale of Celios to Impact BioMedical

DSS (DSS) announced the sale of its Celios air purification asset to Impact BioMedical (IBO) in a strategic, all-equity transaction valued at approximately $1.15M. This divestiture aligns with DSS’ ongoing strategy to optimize its portfolio and concentrate on core growth areas. “The sale of Celios to Impact BioMedical represents another step in our strategic efforts to streamline our holdings and focus on our core business objectives,” said Jason Grady, CEO of DSS, Inc. “Impact BioMedical is well-positioned to leverage Celios’ innovative air purification technology, and we believe this transition will maximize the platform’s potential while allowing DSS to continue to focus into areas with stronger long-term synergies.”